Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats

Kidney and Blood Pressure Research

Volumn 34, Issue 2, 2011, Pages 87-96

  Nagasu, Hajime ^a   Satoh, Minoru ^a   Yorimitsu, Daisuke ^a   Tomita, Naruya ^a   Sasaki, Tamaki ^a   Kashihara, Naoki ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Angiotensin receptor blockers; Azelnidipine; Calcium channel blockers; Chronic kidney disease; Combination therapy; Hydrochlorothiazide; NAD(P)H oxidase activity; Olmesartan; Renal and vascular damage; SHR NDmcr cp rats

Indexed keywords

AZELNIDIPINE; HYDROCHLOROTHIAZIDE; OLMESARTAN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; GLOMERULUS; GLYCOCALYX; HUMAN; HUMAN CELL; KIDNEY; KIDNEY INJURY; METABOLIC SYNDROME X; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; URINARY EXCRETION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AZETIDINECARBOXYLIC ACID; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; HYDROCHLOROTHIAZIDE; IMIDAZOLES; KIDNEY DISEASES; OXIDATIVE STRESS; RATS; RATS, INBRED SHR; TETRAZOLES; VASCULAR DISEASES;

EID: 79151479426     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323535     Document Type: Article

References (40)

1. Fuentes R, Ilmaniemi N, Laurikainen E, Tuomilehto J, Nissinen A: Hypertension in developing economies: a review of populationbased studies carried out from 1980 to 1998. J Hypertens 2000;18:521-529.
2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047. (Pubitemid 350074801)
3. Fan YY, Baba R, Nagai Y, Miyatake A, Hosomi N, Kimura S, Sun GP, Kohno M, Fujita M, Abe Y, Nishiyama A: Augmentation of intrarenal angiotensin ii levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan. Hypertens Res 2006;29:169-178.
4. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
5. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ: Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008-2013. (Pubitemid 29271745)
6. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Gleason A, Heritier S, Li N, Perkovic V, Woodward M, MacMahon S: Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336:1121-1123. (Pubitemid 351731743)
7. Ravandi A, Teo KK: Blocking the renin-angiotensin system: dual- versus mono-therapy. Expert Rev Cardiovasc Ther 2009;7:667-674.
8. Nemeth Z, Kokeny G, Godo M, Mozes M, Rosivall L, Gross ML, Ritz E, Hamar P: Increased renoprotection with ace inhibitor plus aldosterone antagonist as compared to monotherapies - the effect on podocytes. Nephrol Dial Transplant 2009;24:3640-3651.
9. Waanders F, Vaidya VS, van Goor H, Leuvenink H, Damman K, Hamming I, Bonventre JV, Vogt L, Navis G: Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule-1 excretion in nondiabetic proteinuric kidney disease: a post-hoc analysis of a randomized controlled trial. Am J Kidney Dis 2009;53:16-25.
10. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428.
11. Yamaguchi Y, Yamada K, Yoshikawa N, Nakamura K, Haginaka J, Kunitomo M: Corosolic acid prevents oxidative stress, inflammation and hypertension in SHR/NDmcr-cp rats, a model of metabolic syndrome. Life Sci 2006;79:2474-2479. (Pubitemid 44750017)
12. Fan YY, Kohno M, Nakano D, Ohsaki H, Kobori H, Suwarni D, Ohashi N, Hitomi H, Asanuma K, Noma T, Tomino Y, Fujita T, Nishiyama A: Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte. J Hypertens 2010;28:1034-1043.
13. Fujimoto S, Satoh M, Horike H, Hatta H, Haruna Y, Kobayashi S, Namikoshi T, Arakawa S, Tomita N, Kashihara N: Olmesartan ameliorates progressive glomerular injury in subtotal nephrectomized rats through suppression of superoxide production. Hypertens Res 2008;31:305-313. (Pubitemid 351461111)
14. Fujimoto S, Satoh M, Nagasu H, Horike H, Sasaki T, Kashihara N: Azelnidipine exerts renoprotective effects by improvement of renal microcirculation in angiotensin II infusion rats. Nephrol Dial Transplant 2009;24:3651-3658.
15. Namikoshi T, Satoh M, Tomita N, Haruna Y, Kobayashi S, Komai N, Sasaki T, Kashihara N: Pioglitazone ameliorates endothelial dysfunction in obese rats with nephropathy. Biochem Biophys Res Commun 2007;361:835-840. (Pubitemid 47259015)
16. Kobayashi S, Satoh M, Namikoshi T, Haruna Y, Fujimoto S, Arakawa S, Komai N, Tomita N, Sasaki T, Kashihara N: Blockade of serotonin 2a receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy. Clin Exp Nephrol 2008;12:119-125.
17. Satoh M, Ogita H, Takeshita K, Mukai Y, Kwiatkowski DJ, Liao JK: Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci USA 2006;103:7432-7437. (Pubitemid 43727850)
18. Nagasu H, Satoh M, Kuwabara A, Yorimitsu D, Sakuta T, Tomita N, Kashihara N: Renal denervation reduces glomerular injury by suppressing NAD(P)H oxidase activity in Dahl salt-sensitive rats. Nephrol Dial Transplant 2010;25:2889-2898.
19. Namikoshi T, Tomita N, Satoh M, Haruna Y, Kobayashi S, Komai N, Sasaki T, Kashihara N: Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet. Hypertens Res 2008;31:745-755. (Pubitemid 351772866)
20. Kuwabara A, Satoh M, Tomita N, Sasaki T, Kashihara N: Deterioration of glomerular endothelial surface layer induced by oxidative stress is implicated in altered permeability of macromolecules in Zucker fatty rats. Diabetologia 2010;53:2056-2065.
21. Haruna Y, Morita Y, Komai N, Yada T, Sakuta T, Tomita N, Fox DA, Kashihara N: Endothelial dysfunction in rat adjuvant-induced arthritis: vascular superoxide production by NAD(P)H oxidase and uncoupled endothelial nitric oxide synthase. Arthritis Rheum 2006;54:1847-1855. (Pubitemid 43877934)
22. Shinomiya K, Mizushige K, Fukunaga M, Masugata H, Ohmori K, Kohno M, Senda S: Antioxidant effect of a new calcium antagonist, azelnidipine, in cultured human arterial endothelial cells. J Int Med Res 2004;32:170-175. (Pubitemid 38401084)
23. Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T: Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-α-induced interleukin-8 expression in endothelial cells through its antioxidative properties. J Cardiovasc Pharmacol 2004;43:724-730. (Pubitemid 38534074)
24. Tanifuji C, Suzuki Y, Geot WM, Horikoshi S, Takahashi H, Tomino Y: Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys. Kidney Blood Press Res 2009;32:239-249.
25. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M: Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin- converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004;109:2213-2220. (Pubitemid 38625399)
26. Griendling KK, Harrison DG: Out, damned dot: studies of the NADPH oxidase in atherosclerosis. J Clin Invest 2001;108:1423-1424. (Pubitemid 33091978)
27. Satoh M, Fujimoto S, Haruna Y, Arakawa S, Horike H, Komai N, Sasaki T, Tsujioka K, Makino H, Kashihara N: NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 2005;288:F1144-F1152. (Pubitemid 40677084)
28. Satoh M, Haruna Y, Fujimoto S, Sasaki T, Kashihara N: Telmisartan improves endothelial dysfunction and renal autoregulation in Dahl salt-sensitive rats. Hypertens Res 2010;33:135-142.
29. Satoh M, Fujimoto S, Arakawa S, Yada T, Namikoshi T, Haruna Y, Horike H, Sasaki T, Kashihara N: Angiotensin ii type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy. Nephrol Dial Transplant 2008;23:3806-3813.
30. Fonseca FA, Ihara SS, Izar MC, Silva EP, Kasinski N, Lopes IE, Pinto LE, Paiva TB, Tufik S, de Paola AA, Carvalho AC: Hydrochlorothiazide abolishes the anti-atherosclerotic effect of quinapril. Clin Exp Pharmacol Physiol 2003;30:779-785. (Pubitemid 37330526)
31. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ: Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004;65:1568-1576. (Pubitemid 38591003)
32. Gillman MW, Kannel WB, Belanger A, D'Agostino RB: Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993;125:1148-1154. (Pubitemid 23117352)
33. Puchler K, Laeis P, Stumpe KO: Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens Suppl 2001;19:S41-48.
34. Shokoji T, Fujisawa Y, Kiyomoto H, Rahman M, Sun GP, Fan YY, Kimura S, Kohno M, Abe Y, Nishiyama A: Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats. Hypertens Res 2005;28:1017-1023.
35. Ishimitsu T, Numabe A, Masuda T, Akabane T, Okamura A, Minami J, Matsuoka H: Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res 2009;32:962-968.
36. 1 -adrenergic trophic activity in pulmonary artery of hypoxic pulmonary hypertensive rats. Am J Physiol Heart Circ Physiol 2006;291:H2272-H2281.
37. Bleeke T, Zhang H, Madamanchi N, Patterson C, Faber JE: Catecholamine-induced vascular wall growth is dependent on generation of reactive oxygen species. Circ Res 2004;94:37-45. (Pubitemid 38064096)
38. Oelze M, Daiber A, Brandes RP, Hortmann M, Wenzel P, Hink U, Schulz E, Mollnau H, von Sandersleben A, Kleschyov AL, Mulsch A, Li H, Forstermann U, Munzel T: Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 2006;48:677-684. (Pubitemid 44843872)
39. Suzuki J, Iwai M, Li Z, Li JM, Min LJ, Ide A, Yoshii T, Oshita A, Mogi M, Horiuchi M: Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice. J Hypertens 2005;23:1383-1389. (Pubitemid 40933959)
40. Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, Rakugi H, Ogihara T, Horiuchi M: Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 2004;43:263-269. (Pubitemid 38174185)